Research Analysts Issue Forecasts for EVAX FY2024 Earnings

Evaxion Biotech A/S (NASDAQ:EVAX) – Investment analysts at HC Wainwright increased their FY2024 earnings estimates for shares of Evaxion Biotech A/S in a research note issued to investors on Monday, February 3rd. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.14) for the year, up from their previous forecast of ($0.70). HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Evaxion Biotech A/S’s current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Evaxion Biotech A/S’s FY2025 earnings at ($0.01) EPS, FY2026 earnings at ($0.01) EPS, FY2027 earnings at $0.13 EPS and FY2028 earnings at $0.06 EPS.

Separately, Lake Street Capital decreased their price target on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday.

Evaxion Biotech A/S Trading Up 36.3 %

Shares of EVAX stock opened at $3.27 on Wednesday. The company has a 50 day moving average of $4.79 and a 200-day moving average of $10.58. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00. Evaxion Biotech A/S has a 12-month low of $2.22 and a 12-month high of $23.70.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Catalina Capital Group LLC acquired a new stake in Evaxion Biotech A/S (NASDAQ:EVAX) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned approximately 2.98% of Evaxion Biotech A/S at the end of the most recent quarter. 11.04% of the stock is owned by institutional investors.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.